Patent ID: 8685435

Claim:
A drug delivery system for treating an ocular condition, the drug delivery system comprising first, second, and third bioerodible implants suitable for insertion into an ocular region or site, the first bioerodible implant comprising dexamethasone and a poly(D,L-lactide) having an average molecular weight of about 3,500 Daltons; the second bioerodible implant comprising dexamethasone and a poly(D,L-lactide-co-glycolide) having a 75:25 wt %/wt % blend of lactide:glycolide and an average molecular weight of about 40,000 Daltons; and the third bioerodible implant comprising dexamethasone and a poly(D,L-lactide) having an average molecular weight of about 14,000 Daltons, wherein the drug delivery system, when inserted into an ocular region or site, can release a therapeutic level of dexamethasone into the ocular region or site for a period of time between about 30 days and about 1 year.